Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A phase I study of pyrazofurin.

P A Salem, G P Bodey, M A Burgess

    Cancer
    |December 1, 1977
    PubMed
    Summary

    Pyrazofurin treatment for advanced cancer showed dose-related toxicities, primarily stomatitis, which limited dosage. No anti-cancer responses were observed, suggesting further research in specific sensitive cancers is warranted.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    The african organization for research and training in cancer.

    Current oncology (Toronto, Ont.)·2012
    Same author

    A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    Leukemia·2012
    Same author

    The road to cancer control goes through leukemia research.

    Current oncology (Toronto, Ont.)·2009
    Same author

    Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

    Leukemia·2009
    Same author

    Lesson on leukemia.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Advanced disseminated cancer presents significant treatment challenges.
    • Identifying effective and tolerable chemotherapeutic agents is crucial.

    Purpose of the Study:

    • To evaluate toxicity patterns of pyrazofurin in advanced cancer patients.
    • To determine the maximum tolerated dose (MTD) of pyrazofurin.
    • To assess the therapeutic effect of pyrazofurin.

    Main Methods:

    • A Phase I clinical trial involving 61 patients with advanced disseminated cancer.
    • Progressively increasing doses of pyrazofurin administered via intravenous injection over 5-day courses.
    • Courses were repeated every 2-3 weeks, with toxicity and response monitoring.

    Main Results:

    • Stomatitis was the dose-limiting toxicity, occurring in 32 patients.
    • Mild to moderate myelosuppression (leukopenia, thrombocytopenia) was observed, with complete marrow recovery by day 21.
    • Cutaneous toxicity, proctitis, nausea, and vomiting were also noted, with most toxicities being dose-related.
    • No objective anti-cancer responses were observed in evaluable patients.

    Conclusions:

    • A recommended dose schedule of 45 mg/m2/day x 5, repeated every 3 weeks, was established based on tolerable toxicity.
    • Pyrazofurin demonstrated significant toxicities, with stomatitis being dose-limiting.
    • Phase II studies are recommended for cancers known to be sensitive to pyrazofurin.

    Related Experiment Videos